ALTRIA GROUP INC (MO)
Sector: Consumer Staples
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Consumer Staples
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MO
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MO | Other Member; Chair; Director | 68 | ["Retired Executive Vice President, Research & Development and Chief Medical Officer, Becton, Dickinson and Company", "Served as Executive Vice President, Research & Development and Chief Medical Officer of Becton, Dickinson and Company from April 2013 until her retirement in January 2018", "Served as a Senior Advisor to the CEO at GlaxoSmithKline from April 2012 through March 2013", "Held senior executive leadership roles in global product development and commercialization, medical affairs and business development at leading pharmaceutical and medical technology companies including Pfizer, Inc., Novartis AG, Virogen Limited, Bausch & Lomb, Inc. and Merck & Co., Inc."] | ["Executive Committee", "Innovation Committee", "Executive", "Finance", "Innovation (Chair)", "Nominating", "Corporate Governance and Social Responsibility"] | 2026 |
Biography sourced from the proxy statement filing.
Retired Executive Vice President, Research & Development and Chief Medical Officer, Becton, Dickinson and Company Served as Executive Vice President, Research & Development and Chief Medical Officer of Becton, Dickinson and Company, a leading global medical technology company, from April 2013 until her retirement in January 2018. Served as a Senior Advisor to the CEO at GlaxoSmithKline, a global biopharma company, from April 2012 through March 2013, after previously serving as the Senior Vice President and Chief Medical Officer from April 2008 through March 2012. Held senior executive leadership roles in global product development and commercialization, medical affairs and business development at leading pharmaceutical and medical technology companies including Pfizer, Inc., Novartis AG, Virogen Limited, Bausch & Lomb, Inc. and Merck & Co., Inc. prior to 2008. Other Current Public Directorships: Hyperion DeFi, Inc. (NASDAQ: HYPD). Prior Public Company Directorships: None. Other Directorships, Trusteeships and Memberships: Previously served on the boards of Syncona Limited (LSE: SYNC) and Syncona Partners LLP. Director Qualifications: The NCGSR Committee believes that Dr. Strahlman s significant experience in innovation, global product development and commercialization in regulated industries, public company board experience, as well as her medical background and experience in biosciences, provide clear support for her nomination for election to our Board.